Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

A. Cortellini, A. Friedlaender, G.L. Banna, G. Porzio, M. Bersanelli, F. Cappuzzo, J.G.J.V. Aerts, R. Giusti, E. Bria, D. Cortinovis, F. Grossi, M.R. Migliorino, D. Galetta, F. Passiglia, R. Berardi, F. Mazzoni, V. Di Noia, D. Signorelli, A. Tuzi, A. GelibterP. Marchetti, M. Macerelli, F. Rastelli, R. Chiari, D. Rocco, A. Inno, P. Di Marino, G. Mansueto, F. Zoratto, M. Santoni, M. Tudini, M. Ghidini, M. Filetti, A. Catino, P. Pizzutilo, L. Sala, M.A. Occhipinti, F. Citarella, R. Marco, M. Torniai, L. Cantini, A. Follador, V. Sforza, O. Nigro, M.G. Ferrara, E. D'Argento, A. Leonetti, L. Pettoruti, L. Antonuzzo, S. Scodes, L. Landi, G. Guaitoli, C. Baldessari, F. Bertolini, L. Della Gravara, M.G. Dal Bello, R.A. Belderbos, M. De Filippis, C. Cecchi, S. Ricciardi, C. Donisi, A. De Toma, C. Proto, A. Addeo, O. Cantale, B. Ricciuti, C. Genova, A. Morabito, D. Santini, C. Ficorella, K. Cannita

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes'. Together they form a unique fingerprint.

Medicine & Life Sciences